Chevy Chase Trust Holdings LLC Has $66.18 Million Stock Position in Boston Scientific Co. (NYSE:BSX)

Chevy Chase Trust Holdings LLC lessened its stake in Boston Scientific Co. (NYSE:BSX) by 1.6% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 789,772 shares of the medical equipment provider’s stock after selling 13,076 shares during the quarter. Chevy Chase Trust Holdings LLC’s holdings in Boston Scientific were worth $66,183,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the stock. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its stake in Boston Scientific by 4.4% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 4,119,399 shares of the medical equipment provider’s stock worth $345,205,000 after purchasing an additional 173,034 shares during the period. BDF Gestion bought a new stake in shares of Boston Scientific in the second quarter valued at about $3,570,000. Brookstone Capital Management boosted its position in shares of Boston Scientific by 389.1% during the second quarter. Brookstone Capital Management now owns 69,945 shares of the medical equipment provider’s stock worth $5,414,000 after buying an additional 55,645 shares during the period. HWG Holdings LP bought a new position in shares of Boston Scientific during the second quarter worth about $482,000. Finally, PGGM Investments raised its position in Boston Scientific by 9.6% in the 2nd quarter. PGGM Investments now owns 117,794 shares of the medical equipment provider’s stock valued at $9,071,000 after buying an additional 10,366 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Morgan Stanley upped their price target on Boston Scientific from $92.00 to $100.00 and gave the stock an “overweight” rating in a research report on Thursday, October 24th. TD Cowen raised their target price on shares of Boston Scientific from $86.00 to $100.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Bank of America lifted their price target on shares of Boston Scientific from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday, October 22nd. Raymond James increased their price objective on shares of Boston Scientific from $91.00 to $94.00 and gave the stock a “strong-buy” rating in a research note on Wednesday, September 4th. Finally, BTIG Research lifted their target price on Boston Scientific from $84.00 to $93.00 and gave the company a “buy” rating in a research report on Monday, October 14th. Four analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $93.39.

Insider Activity at Boston Scientific

In related news, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $81.70, for a total transaction of $570,511.10. Following the sale, the executive vice president now owns 37,468 shares of the company’s stock, valued at $3,061,135.60. This represents a 15.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Arthur C. Butcher sold 14,010 shares of Boston Scientific stock in a transaction on Monday, November 25th. The shares were sold at an average price of $89.27, for a total value of $1,250,672.70. Following the completion of the transaction, the executive vice president now directly owns 978 shares of the company’s stock, valued at $87,306.06. This represents a 93.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 328,157 shares of company stock worth $27,894,270. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Trading Down 0.1 %

Shares of BSX stock opened at $90.66 on Monday. Boston Scientific Co. has a 12-month low of $53.93 and a 12-month high of $91.93. The company has a market capitalization of $133.62 billion, a PE ratio of 74.93, a price-to-earnings-growth ratio of 2.67 and a beta of 0.79. The firm has a 50 day moving average price of $86.70 and a two-hundred day moving average price of $80.80. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.04. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. The business had revenue of $4.21 billion during the quarter, compared to analysts’ expectations of $4.04 billion. During the same period last year, the firm posted $0.50 EPS. The firm’s revenue for the quarter was up 19.3% compared to the same quarter last year. As a group, analysts predict that Boston Scientific Co. will post 2.46 earnings per share for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.